spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Grupo NotreDame Intermédica (GNDI) of Brazil enhances patient care and improves patient access to leading-edge medications by joining Clinerion’s global network of hospital partners on Patient Network Explorer

Clinerion

Grupo NotreDame Intermédica (GNDI) is the latest hospital group from Brazil to become a partner in Clinerion’s global network on Patient Network Explorer. Their patients gain visibility from researchers and trials sponsors selecting sites for clinical st


Basel, Switzerland, August 30th, 2021 –
Grupo NotreDame Intermédica (GNDI) is the largest healthcare operator in Brazil, with 6.4 million members. Founded in 1968, it is a pioneer in preventive medicine. GNDI has a wide offer, comprising 29 hospitals, 88 clinical centers, 23 autonomous emergency rooms, 15 preventive medicine centers and 2 health centers exclusively dedicated to the over-fifties.

Also part of GNDI is NotreLabs, a national laboratory network with the capability to perform more than 100 operations, distributed across the southern and south-eastern regions of Brazil. NotreLabs also has the capacity to process 4.5 million clinical analyses and 500 thousand imaging exams per month. There are 12 units for imaging exams and 72 collection points for clinical analyses.

Joining Patient Network Explorer, GNDI patients and their treating physicians gain increased treatment options and quicker access to new medical interventions. Patients are matched to academic and sponsored clinical studies according to their electronic health records, ensuring better screening when recruiting for clinical trials. Trial managers gain the ability to include eligible patients for trials more quickly and efficiently than before. Physicians gain tools to better stratify patient care, including the identification of hard-to-diagnose rare disease patients.

“The GNDI Research Institute was created to better serve beneficiaries and reconcile the research objective with advances in clinical treatments within the Group's own service network. Clinerion's tool, Patient Network Explorer, will help us to filter, among all the group’s electronic medical records, patients with the criteria to participate in each type of survey. It is an advance in the screening process that will result in more consistent evaluations for trial recruitment,” says Carina Carraro Pessoa Messias, Coordinator of the Research Institute of Grupo NotreDame Intermédica.

“iHealth, as a partner of Clinerion in Brazil, is determined to connect more and more clinical research reference centers in Brazil, and we are very excited to be partnering with Grupo NotreDame Intermédica. This pandemic has reinforced the importance of clinical research, and as Brazil is 25th in the world for clinical research, we have the potential for much more!” says Leonardo Nunes Alegre, COO of iHealth. “Grupo NotreDame Intermédica is our 21st hospital group partner in Brazil, bringing our Brazil coverage north of 10 million patients,” says Barış Erdoğan, CEO of Clinerion.

“We can truly say that we have the largest coverage on Brazil for EHR-based search. Once again, we thank iHealth Group for their continued support for the Clinerion Community of hospitals in Brazil.”

About Clinerion

Clinerion accelerates clinical research and medical access to treatments for patients. We generate real-world data from our global network of partner hospitals for Real World Evidence analyses. Clinerion's Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments.

Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. Researchers gain access to real-time, longitudinal patient data from electronic health records for analysis. We enable pharmaceutical companies, CROs and SMOs to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s Patient Network Explorer also provides a platform for integration of diverse patient data sources into real-world data ecosystems. Clinerion’s proprietary technologies comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.

Clinerion website: www.clinerion.com

phone +41 61 865 60 60
email info@clinerion.com
web www.clinerion.com/
email Elisabethenanlage 11, 4051 Basel, Switzerland
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Analytical Service Leaders in Biopharmaceutical and Gene Therapy Development Unify Operations and Re-brand as ProtaGene

Heilbronn & Heidelberg, Germany and Boston, USA – January 12, 2022: Following the announced merger in July 2021, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH today announced their unified operations and re-brand as ProtaGene, a world-leading CRO partner for the biopharmaceutical and cell & gene therapy industries.
More info >>


White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement